Podcasts about diabetes research center

Send us a textMichael J. Burton is the CEO of the Diabetes Research Institute Foundation ( https://diabetesresearch.org/ ), a philanthropic organization which funds the Diabetes Research Institute, one of the largest and most comprehensive research centers dedicated to curing diabetes.A passionate nonprofit executive, Michael has more than 30 years of experience in leading high-impact philanthropic programs and cultivating strategic relationships to secure transformative funding. Prior to assuming the role of CEO at DRIF, Michael advanced the missions of some of the nation's most dynamic and trusted institutions including Princeton University, The Pew Charitable Trusts and the American Association for Cancer Research (AACR).Michael's accomplished nonprofit career includes significant contributions in the advancement of cancer research and care, most recently as President and CEO of Gateway for Cancer Research, a Chicago-based nonprofit engaged in funding early phase clinical research, where he began his tenure as Chief Development Officer. Prior to that, Michael served as Chief Development Officer and Executive Director of the Foundation at the AACR, the nation's oldest and largest organization dedicated to the prevention and cure of all cancers. Michael's 15 years of experience in the oncology sector also includes leading the development program at Fox Chase Cancer Center as Senior Vice President and Chief Development Officer.Before working in the field of oncology, Michael had a distinguished career in higher education, most notably at the University of Pennsylvania, where he served as Special Assistant to the President during the tenure of Judith Rodin, the first female president of an Ivy League institution; and at Temple University, where he held the title of Assistant Dean and lead the development program at the Fox School of Business. Before entering higher education, Michael served as Legislative and Press Assistant to the late Congressman Tom Lantos, the only survivor of the Holocaust ever elected to Congress. Michael is a graduate of the University of Pennsylvania, where he earned a Bachelor's degree in Communications and a Master's degree in Public Administration. Prof. Dr. Matthias von Herrath, MD is the Scientific Director of the Diabetes Research Institute (DRI) and Stacy Joy Goodman Chair at the University of Miami School of Medicine ( https://med.miami.edu/faculty/matthias-georg-von-herrath ) where he is leading the DRI mission to conduct and accelerate research to delay, prevent and ultimately find a cure for type 1 diabetes.  He is widely recognized for his groundbreaking work in understanding the molecular mechanisms of T1D, an autoimmune disease in which the body's immune system attacks and destroys insulin-producing beta cells in the pancreas, and developing novel therapies for this disease. Prof. Dr. von Herrath served as a Professor and Director for the Type 1 Diabetes Research Center at La Jolla Institute for Allergy and Immunology, and also currently serves as Vice President and Senior Medical Officer at Novo Nordisk, a global healthcare company, where he is responsible for overseeing the company's research and development efforts in diabetes care.Prof. Dr. von Herrath earned his medical degree in 1988 from Freiburg Medical School, where he also completed a Ph.D. equivalent thesis on biochemistry. His postdoctoral training included an intensive care residency at Diakonie Hospital, Freiburg.#DiabetesResearchInstituteFoundation #T1D #Insulin #IsletCellTransplant #Regeneration #Immunomodulation #Immunoregulation #Autoimmune #UniversityOfMiami #Philanthropy #NovoNordisk #Instacart  #ProgressPotentialAndPossibilities #IraPastor #PodcSupport the show

Welcome to the Green Rush, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture, produced by KCSA Podcast Labs. Today, we have a special episode featuring our newest production, Alternatively Speaking. In our debut season, we're diving into a revolutionary concept in health span, longevity, and healthcare. We met with Dr. Nir Barzilai, director of the Institute for Aging Research at the Albert Einstein College of Medicine and the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health's (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. Dr. Barzilai discovered the first “longevity gene” in humans. His research established that the gene variant that leads to high HDL, or “good cholesterol,” is linked to healthy aging and extreme longevity.  Treatments for age-related diseases like type 2 diabetes are being developed based on Dr. Barzilai's work and are currently in clinical trials. In addition to his “longevity gene” research, Dr. Barzilai studies key mechanisms involved in the biology of aging, including how nutrients and genetics influence lifespan. He is also investigating the physical and mental declines associated with aging and how they affect longevity. Dr. Barzilai is professor of medicine (endocrinology) and of genetics, a member of the Diabetes Research Center, and director of the Diabetes Research and Training Center's Animal Physiology core. Podcast Highlights: Introduction & Dr. Nir Barzilai's Groundbreaking Discovery (00:00 - 03:15): Overview of Dr. Nir Barzilai's discovery of the first “longevity gene” in humans and its link to healthy aging. Discussion on the significance of high HDL cholesterol and how it relates to extreme longevity. The Science Behind Longevity Genes (03:16 - 08:32): Dive into the specific genetic markers that contribute to longevity. Dr. Barzilai shares insights on the mechanisms of aging and the potential to delay or reverse age-related diseases. Current Clinical Trials on Age-Related Diseases (08:33 - 12:10): An exploration of the treatments for type 2 diabetes and other age-related conditions that are being developed from Dr. Barzilai's research, with an update on the progress of these clinical trials. Nutritional and Genetic Influence on Lifespan (12:11 - 17:48): How both genetics and nutrition shape our healthspan and longevity. Dr. Barzilai explains the latest findings on how diet can influence aging and the role of genetics in extending life. Mental and Physical Decline in Aging (17:49 - 21:22): Discussion on the common declines in physical and mental health with aging, and how they impact longevity. Dr. Barzilai talks about ongoing research into mitigating these declines. Future of Longevity Research (21:23 - 26:55): Dr. Barzilai shares his vision for the future of aging research, focusing on potential breakthroughs in longevity science. Social Media: @NirBarzilaiMD: https://x.com/nirbarzilaimd?lang=en  https://www.linkedin.com/in/nir-barzilai-7a86a7212/  Other Links/Mentions/Resources: Age Later by Nir Barzilai, M.D. https://us.macmillan.com/books/9781250230867/agelater  Albert Einstein College of Medicine https://einsteinmed.edu/faculty/484/nir-barzilai  American Federation for Aging Research (AFAR) https://www.afar.org/ Aging is a Treatable Condition - Worth.com The 4 most promising anti-aging drugs investors are sleeping on, according to a leading longevity researcher - Business Insider What is your Biological Age? - The New York Times Show Credits: This episode was hosted by Anne Donohoe and Phil Carlson of KCSA Strategic Communications.  Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas. You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing greenrush@kcsa.com.

W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham and the principal investigator of SURMOUNT-2, joins our hosts to provide perspective on several topics, including the FDA's approval of tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more. Key Timestamps 01:04 - Guest Introduction 03:45 - FDA Indication for Obesity 08:45 - SURMOUNT-2 17:40 - SURMOUNT-3 and -4 22:00 - Future of Incretin Therapies

Dr. Nir Barzilai, MD ( https://www.einsteinmed.edu/faculty/484/nir-barzilai/ ) is the Director of the Institute for Aging Research at the Albert Einstein College of Medicine and the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health's (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. He is the Ingeborg and Ira Leon Rennert Chair of Aging Research, professor in the Departments of Medicine and Genetics, and member of the Diabetes Research Center and of the Divisions of Endocrinology & Diabetes and Geriatrics. Dr. Barzilai's research interests are in the biology and genetics of aging, with one focus of his team on the genetics of exceptional longevity, where they hypothesize and demonstrate that centenarians (those aged 100 and above) may have novel protective genes, which allow the delay of aging or for the protection against age-related diseases. The second focus of his work, for which Dr. Barzilai holds an NIH Merit award, is on the metabolic decline that occurs during aging, and his team hypothesizes that the brain leads this decline with some very interesting neuro-endocrine connections. Dr. Barzilai is currently leading an international effort to approve drugs that can target aging (Gerotherapeutics). Targeting Aging with METformin (TAME) is a specific study designed to prove the concept that a basket of diseases (multi-morbidities) of aging can be delayed simultaneously, in this protocol by the drug metformin, working with the FDA to approve this approach which will serve as a template for future efforts to delay aging and its diseases in humans. Dr. Barzilai has received numerous grants, among them ones from the National Institute on Aging (NIA), American Federation for Aging Research, the Ellison Medical Foundation and The Glenn Medical foundation. He has published over 280 peer-reviewed papers, reviews, and textbook chapters. He is an advisor to the NIH on several projects and serves on several editorial boards and is a reviewer for numerous other journals. Dr. Barzilai is on the board of the American Federation for Aging Research, is it's co-scientific director, and has served on several NIA study sections. He is also a founder of CohBar Inc., a biotech company that develops mitochondrial derived peptides as therapy for aging and it's diseases, and of Life Biosciences. Dr. Barzilai has been the recipient of numerous prestigious awards, including the Beeson Fellow for Aging Research, the Ellison Medical Foundation Senior Scholar in Aging Award, the Paul F. Glenn Foundation Award, the NIA Nathan Shock Award, the 2010 Irving S. Wright Award of Distinction in Aging Research and the IPSEN Longevity Prize (2016). Born in Israel, Dr. Barzilai served as chief medic and physician in the Israel Defense Forces. He graduated from The Ruth and Bruce Rappaport Faculty of Medicine at the Technion-Israel Institute of Technology in Haifa and completed his residency in internal medicine at Hadassah Medical Center in Jerusalem. He served in a refugee camp during the war in Cambodia (1979-1980) and built a nutritional village in the homeland of the Zulu (1983 – Kwazulu). He has completed 2 fellowships at Yale (Metabolism) and Cornell (Endocrinoology and Molecular Medicine).  He has also taken part in Global initiatives and spoke at The Milken Global Institute, Asian Megatrends and is an advisor for the Prime Minister of Singapore on Aging. Dr. Barzilai has been on the ‘Forward 50, top 50 influence Jews" in the US (2011). His work has been profiled by major outlets, including the New York Times, the BBC and PBS' NOVA science now, TEDMED and several TEDx talks, and is the leading feature on the Ron Howard/Jonathan Silberberg/National Geographic film about the Age of Aging. He also authored the book Age Later (2019). Support the show

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Gerald Shulman is a Professor of Medicine, Cellular & Molecular Physiology, and the Director of the Diabetes Research Center at Yale. His pioneering work on the use of advanced technologies to analyze metabolic flux within cells has greatly contributed to the understanding of insulin resistance and type 2 diabetes. In this episode, Gerald clarifies what insulin resistance means as it relates to the muscle and the liver, and the evolutionary reason for its existence. He goes into depth on mechanisms that lead to and resolve insulin resistance, like the role of diet, exercise, and pharmacological agents. As a bonus, Gerald concludes with insights into Metformin's mechanism of action and its suitability as a longevity agent. We discuss: Gerald's background and interest in metabolism and insulin resistance (2:30); Insulin resistance as a root cause of chronic disease (6:30); How Gerald uses NMR to see inside cells (10:00); Defining and diagnosing insulin resistance and type 2 diabetes (17:15); The role of lipids in insulin resistance (29:15); Confirmation of glucose transport as the root problem in lipid-induced insulin resistance (38:15); The role of exercise in protecting against insulin resistance and fatty liver (48:00); Insulin resistance in the liver (1:05:00); The evolutionary explanation for insulin resistance—an important tool for surviving starvation (1:15:15); The critical role of gluconeogenesis, and how it's regulated by insulin (1:20:30); Inflammation and body fat as contributing factors to insulin resistance (1:30:15); Treatment approaches for fatty liver and insulin resistance, and an exciting new pharmacological approach (1:39:15); Metformin's mechanism of action and its suitability as a longevity agent (1:56:15); and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Dr. Ben Bikman heads the Diabetes Research Center at BYU, and literally wrote the book on insulin. His book, “Why We Get Sick”, explains the health impacts of having too much insulin, and what you can do about it.In this interview, we discuss how insulin resistance has become insanely common, and how it drives many modern health conditions, including type 2 diabetes, high blood pressure, dementia / Alzheimer's, polycystic ovary syndrome, and more. Dr. Bikman explains how to know if you have too much insulin, even without a blood test.  He also shares practical tips about the most impactful things you can do to improve your metabolic health, including specific nutritional advice (his “4 Pillars”), stress management, sleep, and exercise.YouTube version here:  https://youtu.be/idXljqNpskA Full show notes and resources here:  https://fastingwell.com/episode18/

Dr. Nir Barzilai is the director of the Institute for Aging Research at the Albert Einstein College of Medicine and the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health's (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. He is the Ingeborg and Ira Leon Rennert Chair of Aging Research, professor in the Departments of Medicine and Genetics, and member of the Diabetes Research Center and of the Divisions of Endocrinology & Diabetes and Geriatrics. Speakers: Nir Barzilai and Tim Peterson Hosts: Max Unfried and Morten Scheibye-Knudsen VitaDAO is the world's first decentralized intellectual property collective, funding and commissioning research into human longevity

Drive with Dr. Peter Attia Podcast Notes Key Takeaways “If we are going to be serious about the business of delaying onset of death, we have to be serious about the business of delaying the onset of chronic disease.” – Peter AttiaInsulin resistance is the root cause of diabetes and downstream chronic diseaseDiabetes amplifies atherosclerotic disease, Alzheimer’s disease, and cancerAbout 50% of people with insulin resistance are asymptomaticYoung, lean adults are presenting with profound insulin resistance in muscle with no problems in the liverUnderstanding insulin resistance will be critical for preventing and treating disease Nuclear Magnetic Resonance (NMR) allows us to get biochemical information of metabolites (i.e., glucose) and key intermediates inside cellsRead the full notes @ podcastnotes.org Gerald Shulman is a Professor of Medicine, Cellular & Molecular Physiology, and the Director of the Diabetes Research Center at Yale. His pioneering work on the use of advanced technologies to analyze metabolic flux within cells has greatly contributed to the understanding of insulin resistance and type 2 diabetes. In this episode, Gerald clarifies what insulin resistance means as it relates to the muscle and the liver, and the evolutionary reason for its existence. He goes into depth on mechanisms that lead to and resolve insulin resistance, like the role of diet, exercise, and pharmacological agents. As a bonus, Gerald concludes with insights into Metformin’s mechanism of action and its suitability as a longevity agent. We discuss: Gerald’s background and interest in metabolism and insulin resistance (4:30); Insulin resistance as a root cause of chronic disease (8:30); How Gerald uses NMR to see inside cells (12:00); Defining and diagnosing insulin resistance and type 2 diabetes (19:15); The role of lipids in insulin resistance (31:15); Confirmation of glucose transport as the root problem in lipid-induced insulin resistance (40:15); The role of exercise in protecting against insulin resistance and fatty liver (50:00); Insulin resistance in the liver (1:07:00); The evolutionary explanation for insulin resistance—an important tool for surviving starvation (1:17:15); The critical role of gluconeogenesis, and how it’s regulated by insulin (1:22:30); Inflammation and body fat as contributing factors to insulin resistance (1:32:15); Treatment approaches for fatty liver and insulin resistance, and an exciting new pharmacological approach (1:41:15); Metformin’s mechanism of action and its suitability as a longevity agent (1:58:15); More. Learn more: https://peterattiamd.com/ Show notes page for this episode:  https://peterattiamd.com/geraldshulman  Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.

Gerald Shulman is a Professor of Medicine, Cellular & Molecular Physiology, and the Director of the Diabetes Research Center at Yale. His pioneering work on the use of advanced technologies to analyze metabolic flux within cells has greatly contributed to the understanding of insulin resistance and type 2 diabetes. In this episode, Gerald clarifies what insulin resistance means as it relates to the muscle and the liver, and the evolutionary reason for its existence. He goes into depth on mechanisms that lead to and resolve insulin resistance, like the role of diet, exercise, and pharmacological agents. As a bonus, Gerald concludes with insights into Metformin’s mechanism of action and its suitability as a longevity agent. We discuss: Gerald’s background and interest in metabolism and insulin resistance (4:30); Insulin resistance as a root cause of chronic disease (8:30); How Gerald uses NMR to see inside cells (12:00); Defining and diagnosing insulin resistance and type 2 diabetes (19:15); The role of lipids in insulin resistance (31:15); Confirmation of glucose transport as the root problem in lipid-induced insulin resistance (40:15); The role of exercise in protecting against insulin resistance and fatty liver (50:00); Insulin resistance in the liver (1:07:00); The evolutionary explanation for insulin resistance—an important tool for surviving starvation (1:17:15); The critical role of gluconeogenesis, and how it’s regulated by insulin (1:22:30); Inflammation and body fat as contributing factors to insulin resistance (1:32:15); Treatment approaches for fatty liver and insulin resistance, and an exciting new pharmacological approach (1:41:15); Metformin’s mechanism of action and its suitability as a longevity agent (1:58:15); More. Learn more: https://peterattiamd.com/ Show notes page for this episode:  https://peterattiamd.com/geraldshulman  Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.

This week we are joined by Seth Berkowitz to talk about his research examining the associations between food insecurity and health outcomes. Seth is a primary care physician, Instructor of Medicine, and is on faculty in the Division of General Internal Medicine and the Diabetes Research Center at Massachusetts General Hospital. Seth’s research interests include population management, food insecurity, cost-related medication underuse and the impact of adverse social circumstances on chronic disease management. His goal is to develop and disseminate interventions and care delivery models that address social and economic needs. Today he joins us to talk about a recent collaboration, funded by an award from the Robert Wood Johnson Foundation Evidence for Action Program, with Community Servings. Community Servings is a Boston-based non-profit organization dedicated to bringing medically tailored meals to chronically ill adults. The study aims to assess whether individuals receiving the medically tailored meals have lower rates of inpatient hospitalization, ED utilization, and medical expenditures. You can find a piece co-authored by Seth and David Waters, the CEO of Community Servings here, and the Health Affairs article Seth and I talked about examining the effect of eliminating use of SNAP, or food stamps, for sugary sweetened beverages here. Lastly, if you like the show, please rate and review us on itunes or stitcher, which makes the show easier for others to find; and share us on social media. We tweet at @rospodcast and are on facebook at www.facebook.com/reviewofsystems. Please drop us a line at contact@rospod.org. We’d love to hear from you.

November is National Diabetes Month, and this month Dr. Aaron Carroll, is talking to Dr. Raghu Mirmira. Dr. Mirmira is the Eli Lilly Professor in Pediatric Diabetes and Director of the Diabetes Research Center at Indiana University Health in Indianapolis, IN. You'll learn about Type I and Type II diabetes, and the ways people develop the disease.  The Healthcare Triage podcast is sponsored by Indiana University School of Medicine whose mission is to advance health in the state of Indiana and beyond by promoting innovation and excellence in education, research and patient care. IU School of Medicine is leading Indiana University's first grand challenge, the Precision Health Initiative, with bold goals to cure multiple myeloma, triple negative breast cancer and childhood sarcoma and prevent type 2 diabetes and Alzheimer’s disease.

Obesity and weight loss are notoriously challenging areas of research and intervention. Traditional behavioral psychology methods for weight loss are known to be ineffective in the long-term for many people. At a time of year when many of us are resolving to eat better, exercise more, and lose weight, obesity and weight loss expert Dr. Jason Lillis offers a different, evidence-based perspective on this complicated issue. In this interview, cross-posted from the podcast Psychologists Off The Clock, Dr. Diana Hill interview Dr. Lillis about his book, The Diet Trap: Feed Your Psychological Needs and End the Weight Loss Struggle Using Acceptance and Commitment Therapy (New Harbinger Publications, 2014).Dr. Lillis discusses his own values-based reasons for studying obesity, the importance of behavioral interventions, why the “weight loss agenda” may be an ineffective trap, and how values can support long-term commitment to health behaviors. Dr. Lillis also talks about two exercises from ACT that can help people with body appreciation and values-directed behaviors. Jason Lillis is an assistant professor at the Weight Control and Diabetes Research Center at Brown Medical School and the Miriam Hospital. He is a leading ACT researcher who is currently running NIH grants aimed at developing and testing ACT methods for health behavior change, with a specific focus on weight control and physical activity. He is the author of three books:The Diet Trap, Acceptance and Commitment Therapy (Theories of Psychotherapy), and Mindfulness and Acceptance for Treating Eating Disorders and Weight Concerns, and is an editor for the Journal of Contextual Behavioral Science. Diana Hill, Ph.D. is a licensed psychologist practicing in Santa Barbara, California, and a co-host of the podcast Psychologists Off The Clock.   Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychology

Obesity and weight loss are notoriously challenging areas of research and intervention. Traditional behavioral psychology methods for weight loss are known to be ineffective in the long-term for many people. At a time of year when many of us are resolving to eat better, exercise more, and lose weight, obesity and weight loss expert Dr. Jason Lillis offers a different, evidence-based perspective on this complicated issue. In this interview, cross-posted from the podcast Psychologists Off The Clock, Dr. Diana Hill interview Dr. Lillis about his book, The Diet Trap: Feed Your Psychological Needs and End the Weight Loss Struggle Using Acceptance and Commitment Therapy (New Harbinger Publications, 2014).Dr. Lillis discusses his own values-based reasons for studying obesity, the importance of behavioral interventions, why the “weight loss agenda” may be an ineffective trap, and how values can support long-term commitment to health behaviors. Dr. Lillis also talks about two exercises from ACT that can help people with body appreciation and values-directed behaviors. Jason Lillis is an assistant professor at the Weight Control and Diabetes Research Center at Brown Medical School and the Miriam Hospital. He is a leading ACT researcher who is currently running NIH grants aimed at developing and testing ACT methods for health behavior change, with a specific focus on weight control and physical activity. He is the author of three books:The Diet Trap, Acceptance and Commitment Therapy (Theories of Psychotherapy), and Mindfulness and Acceptance for Treating Eating Disorders and Weight Concerns, and is an editor for the Journal of Contextual Behavioral Science. Diana Hill, Ph.D. is a licensed psychologist practicing in Santa Barbara, California, and a co-host of the podcast Psychologists Off The Clock.   Learn more about your ad choices. Visit megaphone.fm/adchoices

Are You Interested In A Fresh Perspective On Weight Loss In The New Year? Do You Wonder If Your Efforts To "fix" Your Weight Problem May Be Making Things Worse? Are You Looking For Motivation That Will Be Long-Standing And Effective? Join Us For An Interview With Dr. Jason Lillis, Acclaimed Weight Loss Researcher And Author Of The Diet Trap! At a time when many of us are resolving to eat better, exercise more, and lose weight, Jason Lillis, Ph.D. offers a fresh and evidence-based perspective on what has been a lifelong struggle for many. In this episode, Diana interviews Dr. Lillis on Acceptance and Commitment Therapy (ACT) for weight management. Dr. Lillis discusses his own values-based reasons for studying obesity, why the "weight loss agenda" may be an ineffective trap, and how values can support long-term commitment to health behaviors. Dr. Lillis also shares two experiential exercises that you can do at home to increase body appreciation and values-directed behaviors. Jason Lillis is an assistant professor at the Weight Control and Diabetes Research Center at Brown Medical School and the Miriam Hospital. He is a leading ACT researcher who is currently running NIH grants aimed at developing and testing ACT methods for health behavior change, with a specific focus on weight control and physical activity. He is the author of 3 books (links below): Acceptance and Commitment Therapy, The Diet Trap, and Mindfulness and Acceptance for Treating Eating Disorders and Weight Concerns, and is an editor for the Journal of Contextual Behavioral Science.  Resources: Listen to Diana guide you in a body compassion exercise here! Learn More about Dr. Jason Lillis Acceptance and Commitment Therapy (Theories of Psychotherapy) by Steven Hayes and Jason Lillis The Diet Trap: Feed Your Psychological Needs and End the Weight Loss Struggle Using Acceptance and Commitment Therapy by Jason Lillis, JoAnne Dahl and Sandra M. Weineland Mindfulness and Acceptance for Treating Eating Disorders and Weight Concerns by Anne Haynos, Evan M. Forman, Meghan L. Butryn, and Jason Lillis

Part 2: Future Treatment Options and Roles for Pharmacists in Individualizing Insulin Therapy In Part 2 of this two-part “Engaging the Experts” interview, William Zellmer talks with Curtis L. Triplitt, Susan Cornell, and Joshua J. Neumiller regarding future treatment options for type 2 diabetes and the roles for pharmacists in individualizing insulin therapy. This installment is produced by ASHP Advantage and supported by Novo Nordisk Inc. Faculty: Curtis Triplitt, PharmD, CDE Associate Director, Diabetes Research Center, Texas Diabetes Institute Associate Professor, Department of Medicine, Division of Diabetes University of Texas Health Science Center at San Antonio San Antonio, Texas Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Director of Experiential Education Associate Professor, Department of Pharmacy Practice Midwestern University Chicago College of Pharmacy Downers Grove, Illinois Joshua Neumiller, PharmD, CDE, FASCP Vice Chair and Associate Professor, Department of Pharmacotherapy Washington State University College of Pharmacy Spokane, Washington C.E. Credits: This activity is not eligible for continuing education credits.

Part 1: Barriers to Optimizing the Use of Insulin in Managing Type 2 Diabetes In Part 1 of this two-part “Engaging the Experts” interview, William Zellmer talks with Curtis L. Triplitt, Susan Cornell, and Joshua J. Neumiller regarding the barriers to optimizing the use of insulin in managing patients with type 2 diabetes. This installment is produced by ASHP Advantage and supported by Novo Nordisk Inc. Faculty: Curtis Triplitt, PharmD, CDE Associate Director, Diabetes Research Center, Texas Diabetes Institute Associate Professor, Department of Medicine, Division of Diabetes University of Texas Health Science Center at San Antonio San Antonio, Texas Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Director of Experiential Education Associate Professor, Department of Pharmacy Practice Midwestern University Chicago College of Pharmacy Downers Grove, Illinois Joshua Neumiller, PharmD, CDE, FASCP Vice Chair and Associate Professor, Department of Pharmacotherapy Washington State University College of Pharmacy Spokane, Washington C.E. Credits: This activity is not eligible for continuing education credits.

Dr. Jean Louis Selam is at the Diabetes Research Center near Los Angeles, which does clinical studies on Type 1 and Type 2 diabetes.Dr. Selam received his undergraduate education and medical doctorate in France, University of Montpelier. He has been a specialist in internal medicine and endocrinology in France since 1979 and licensed in California since 1987. He has worked as an associate professor at University of California Irvine Diabetes Research Program 1986-90 then as an associate professor at University Medical School of Paris, dept of Diabetology 1990-2003. He was appointed in 2005 as Visiting Professor by the USC School of Medicine, Los Angeles.He is the Editor in Chief of the Journals Infusystems, which he founded in 1983, a world leading journal in the field of insulin delivery systems.

Dr. Jean Louis Selam is at the Diabetes Research Center near Los Angeles, which does clinical studies on Type 1 and Type 2 diabetes. Dr. Selam received his undergraduate education and medical doctorate in France, University of Montpelier. He has been a specialist in internal medicine and endocrinology in France since 1979 and licensed in California since 1987. He has worked as an associate professor at University of California Irvine Diabetes Research Program 1986-90 then as an associate professor at University Medical School of Paris, dept of Diabetology 1990-2003. He was appointed in 2005 as Visiting Professor by the USC School of Medicine, Los Angeles. He is the Editor in Chief of the Journals Infusystems, which he founded in 1983, a world leading journal in the field of insulin delivery systems.

Dr. Jean Louis Selam is at the Diabetes Research Center near Los Angeles, which does clinical studies on Type 1 and Type 2 diabetes.Dr. Selam received his undergraduate education and medical doctorate in France, University of Montpelier. He has been a specialist in internal medicine and endocrinology in France since 1979 and licensed in California since 1987. He has worked as an associate professor at University of California Irvine Diabetes Research Program 1986-90 then as an associate professor at University Medical School of Paris, dept of Diabetology 1990-2003. He was appointed in 2005 as Visiting Professor by the USC School of Medicine, Los Angeles.He is the Editor in Chief of the Journals Infusystems, which he founded in 1983, a world leading journal in the field of insulin delivery systems.

Dr. Jean Louis Selam is at the Diabetes Research Center near Los Angeles, which does clinical studies on Type 1 and Type 2 diabetes. Dr. Selam received his undergraduate education and medical doctorate in France, University of Montpelier. He has been a specialist in internal medicine and endocrinology in France since 1979 and licensed in California since 1987. He has worked as an associate professor at University of California Irvine Diabetes Research Program 1986-90 then as an associate professor at University Medical School of Paris, dept of Diabetology 1990-2003. He was appointed in 2005 as Visiting Professor by the USC School of Medicine, Los Angeles. He is the Editor in Chief of the Journals Infusystems, which he founded in 1983, a world leading journal in the field of insulin delivery systems.

William Zellmer talks with Susan Cornell and Curtis Triplitt about SGLT2 inhibitors, one of the newest classes of oral diabetes medications. With an increasing number of both oral and injectable medications, the faculty explore how SGLT2 inhibitors fit into clinical practice. Faculty: Susan Cornell, Pharm.D., CDE, FAPhA, FAADE, Activity Chair Assistant Director of Experiential Education Associate Professor Department of Pharmacy Practice Midwestern University Chicago College of Pharmacy Downers Grove, Illinois Curtis L. Triplitt, Pharm.D., CDE Associate Director, Diabetes Research Center, Texas Diabetes Institute Associate Professor, Department of Medicine, Division of Diabetes University of Texas Health Science Center at San Antonio San Antonio, Texas C.E. Credits: This activity is not eligible for continuing education credits.

William Zellmer talks with Susan Cornell and Curtis Triplitt about SGLT2 inhibitors, one of the newest classes of oral diabetes medications. With an increasing number of both oral and injectable medications, the faculty explore how SGLT2 inhibitors fit into clinical practice. Faculty: Susan Cornell, Pharm.D., CDE, FAPhA, FAADE, Activity Chair Assistant Director of Experiential Education Associate Professor Department of Pharmacy Practice Midwestern University Chicago College of Pharmacy Downers Grove, Illinois Curtis L. Triplitt, Pharm.D., CDE Associate Director, Diabetes Research Center, Texas Diabetes Institute Associate Professor, Department of Medicine, Division of Diabetes University of Texas Health Science Center at San Antonio San Antonio, Texas C.E. Credits: This activity is not eligible for continuing education credits.

Curtis Triplitt discusses with Carla Brink, Scientific Project Director for ASHP, recommended target glucose levels in guidelines for inpatient glycemic control. The interview was conducted in December 2013 during the ASHP Midyear Clinical Meeting. Faculty: Curtis L. Triplitt, Pharm.D., CDE, Activity Chair Associate Director, Diabetes Research Center, Texas Diabetes Institute Associate Professor, Department of Medicine, Division of Diabetes University of Texas Health Science Center at San Antonio San Antonio, Texas C.E. Credits: This activity is not eligible for continuing education credits.

http://www.einstein.yu.edu - Jeffrey Pessin, Ph.D., discusses basic and clinical diabetes research being conducted at Einstein and Montefiore Medical Center, including the brain’s influence on appetite, autoimmune and stem cell therapies, and the efforts to develop an artificial pancreas. Dr. Pessin is director of Einstein’s Diabetes Research Center. This edition of Einstein On is hosted by Gordon Earle, associate dean for communications and public affairs.

http://www.einstein.yu.edu - Jeffrey Pessin, Ph.D., explains the causes and treatments for type 1 diabetes, type 2 diabetes and malnutrition diabetes, a growing problem in the developing world. He also addresses the spiking rates of type 2 diabetes in the U.S. Dr. Pessin is director of the Diabetes Research Center at Albert Einstein College of Medicine. This edition of Einstein On is hosted by Gordon Earle, associate dean for communications and public affairs.

Guest: Kathleen "Kittie" Wyne, MD, PhD, FACE Host: Farhad Zangeneh, MD Host Dr. Farhad Zangeneh welcomes Dr. Kathleen "Kittie" Wyne from the The Methodist Hospital Research Institute (TMHRI) in Houston where she also coordinates their clinical research program in The Diabetes Research Center. Dr. Wyne discusses the changing classification of diabetes and pre-diabetes and how and when we should make the diagnosis. She also discusses the criteria for both diabetes and pre-diabetes and the tools available for clinicians.